Market news

Bioventus benefits from improved financing flexibility, with a term loan maturity extended to 2030 and a 75 bps interest margin reduction. See why BVS is a Buy.

Here is how Bioventus (BVS) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.

Motley Fool Press Release.

Bioventus stock has delivered strong share price gains over the past few years, yet current valuation checks still suggest it screens as relatively cheap on several metrics. That combination of a big historical return with an apparently supportive valuation is what current and prospective shareholders are trying to interpret. Over the last 3 years Bioventus has returned about 198%, which puts a spotlight on whether the current price already reflects much of the good news that investors...

In early August 2026, Bioventus Inc. reported second-quarter sales of US$153.21 million and net income of US$33.44 million, sharply higher than a year earlier, and reaffirmed its full-year 2026 net sales guidance of US$600 million to US$610 million. The combination of rising sales, a substantial jump in earnings per share, and management’s confidence in its 2026 outlook highlights improved operational performance and profitability momentum across Bioventus’ portfolio. Now we’ll examine how...

Bioventus (BVS) has an average rating of buy and mean price target of $15.20, according to analysts

Bioventus Inc (BVS) delivers solid Q2 with 4% revenue growth, reduces leverage below 2x, and announces strategic review following unsolicited acquisition interest.

Bioventus (BVS) delivered earnings and revenue surprises of 0.00% and -1.16%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Q2 reported revenue of $153.2 million increased 4%Q2 GAAP earnings of $0.47 per diluted share compared to the prior-year period earnings of $0.11 per...

Bioventus (NASDAQ:BVS) reported second-quarter 2026 revenue growth of 4% and reiterated its full-year financial outlook, citing double-digit expansion in its Pain Treatments business, continued debt reduction and increased investment in platelet-rich plasma, peripheral nerve stimulation, Ultrasonics

Bioventus (BVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here is how Bioventus (BVS) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.

The consensus price target hints at a 28.9% upside potential for Bioventus (BVS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Bioventus (BVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

After a strong three year share price run, Bioventus now screens as overvalued on market multiples, while its broader valuation checks point to a more nuanced picture rather than a clear bubble or a clear bargain. Bioventus has returned about 234.6% over the past three years, which puts recent valuation concerns in the context of a stock that has already delivered very strong gains for existing shareholders. Recent positive sentiment around earnings expectations can support the current...

The mean of analysts' price targets for Bioventus (BVS) points to a 28.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Does Bioventus (BVS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Detailed price information for Bioventus Inc Cl A (BVS-Q) from The Globe and Mail including charting and trades.

Detailed price information for Bioventus Inc Cl A (BVS-Q) from The Globe and Mail including charting and trades.

Bioventus (BVS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.